Xeris Biopharma Holdings (XERS) Interest & Investment Income (2020 - 2026)

Xeris Biopharma Holdings (XERS) has reported Interest & Investment Income for 7 consecutive years, with $1.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Interest & Investment Income rose 53.48% year-over-year to $1.5 million; the trailing twelve-month figure through Jun 2026 stood at $5.3 million (up 24.73% YoY), and the FY2025 full-year result was $4.7 million, down 10.88% from the prior year.
• Interest & Investment Income rose to $1.5 million in Q2 2026 per XERS's latest filing, from $1.2 million in the prior quarter.
• Across five years, Interest & Investment Income topped out at $1.9 million in Q1 2024 and bottomed at $68000.0 in Q1 2022.
• Historically, Interest & Investment Income has averaged $1.1 million across 5 years, with a median of $1.2 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Interest & Investment Income soared 2532.86% in 2022, then tumbled 39.93% in 2023.
• Over 5 years, Interest & Investment Income stood at $1.8 million in 2022, then slumped by 39.93% to $1.1 million in 2023, then dropped by 17.8% to $910000.0 in 2024, then jumped by 60.55% to $1.5 million in 2025, then dropped by 0.41% to $1.5 million in 2026.
• According to Business Quant data, Interest & Investment Income over the past three periods registered $1.5 million, $1.2 million, and $1.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.